Cargando…
Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program
BACKGROUND: The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for severe acute respiratory syndrome coronavirus 2 (SARS-...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406874/ https://www.ncbi.nlm.nih.gov/pubmed/34111244 http://dx.doi.org/10.1093/cid/ciab537 |
_version_ | 1783746567921991680 |
---|---|
author | Stone, Mars Di Germanio, Clara Wright, David J Sulaeman, Hasan Dave, Honey Fink, Rebecca V Notari, Edward P Green, Valerie Strauss, Donna Kessler, Debbie Destree, Mark Saa, Paula Williamson, Phillip C Simmons, Graham Stramer, Susan L Opsomer, Jean Jones, Jefferson M Kleinman, Steven Busch, Michael P |
author_facet | Stone, Mars Di Germanio, Clara Wright, David J Sulaeman, Hasan Dave, Honey Fink, Rebecca V Notari, Edward P Green, Valerie Strauss, Donna Kessler, Debbie Destree, Mark Saa, Paula Williamson, Phillip C Simmons, Graham Stramer, Susan L Opsomer, Jean Jones, Jefferson M Kleinman, Steven Busch, Michael P |
author_sort | Stone, Mars |
collection | PubMed |
description | BACKGROUND: The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in blood donors in 6 US metropolitan regions to estimate the extent of SARS-CoV-2 infections over time. METHODS: During March–August 2020, approximately ≥1000 serum specimens were collected monthly from each region and tested for SARS-CoV-2 antibodies using a well-validated algorithm. Regional seroprevalence estimates were weighted based on demographic differences compared with the general population. Seroprevalence was compared with reported coronavirus disease 2019 (COVID-19) case rates over time. RESULTS: For all regions, seroprevalence was <1.0% in March 2020. New York, New York, experienced the biggest increase (peak seroprevalence, 15.8% in May). All other regions experienced modest increases in seroprevalence (1%–2% in May–June to 2%–4% in July–August). Seroprevalence was higher in younger, non-Hispanic black, and Hispanic donors. Temporal increases in donor seroprevalence correlated with reported case rates in each region. In August, 1.3–5.6 estimated cumulative infections (based on seroprevalence data) per COVID-19 case were reported to the Centers for Disease Control and Prevention. CONCLUSIONS: Increases in seroprevalence were found in all regions, with the largest increase in New York. Seroprevalence was higher in non-Hispanic black and Hispanic than in non-Hispanic white blood donors. SARS-CoV-2 antibody testing of blood donor samples can be used to estimate the seroprevalence in the general population by region and demographic group. The methods derived from the RESPONSE seroprevalence study served as the basis for expanding SARS-CoV-2 seroprevalence surveillance to all 50 states and Puerto Rico. |
format | Online Article Text |
id | pubmed-8406874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84068742021-09-01 Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program Stone, Mars Di Germanio, Clara Wright, David J Sulaeman, Hasan Dave, Honey Fink, Rebecca V Notari, Edward P Green, Valerie Strauss, Donna Kessler, Debbie Destree, Mark Saa, Paula Williamson, Phillip C Simmons, Graham Stramer, Susan L Opsomer, Jean Jones, Jefferson M Kleinman, Steven Busch, Michael P Clin Infect Dis Major Articles and Commentaries BACKGROUND: The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic (RESPONSE) seroprevalence study conducted monthly cross-sectional testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in blood donors in 6 US metropolitan regions to estimate the extent of SARS-CoV-2 infections over time. METHODS: During March–August 2020, approximately ≥1000 serum specimens were collected monthly from each region and tested for SARS-CoV-2 antibodies using a well-validated algorithm. Regional seroprevalence estimates were weighted based on demographic differences compared with the general population. Seroprevalence was compared with reported coronavirus disease 2019 (COVID-19) case rates over time. RESULTS: For all regions, seroprevalence was <1.0% in March 2020. New York, New York, experienced the biggest increase (peak seroprevalence, 15.8% in May). All other regions experienced modest increases in seroprevalence (1%–2% in May–June to 2%–4% in July–August). Seroprevalence was higher in younger, non-Hispanic black, and Hispanic donors. Temporal increases in donor seroprevalence correlated with reported case rates in each region. In August, 1.3–5.6 estimated cumulative infections (based on seroprevalence data) per COVID-19 case were reported to the Centers for Disease Control and Prevention. CONCLUSIONS: Increases in seroprevalence were found in all regions, with the largest increase in New York. Seroprevalence was higher in non-Hispanic black and Hispanic than in non-Hispanic white blood donors. SARS-CoV-2 antibody testing of blood donor samples can be used to estimate the seroprevalence in the general population by region and demographic group. The methods derived from the RESPONSE seroprevalence study served as the basis for expanding SARS-CoV-2 seroprevalence surveillance to all 50 states and Puerto Rico. Oxford University Press 2021-06-10 /pmc/articles/PMC8406874/ /pubmed/34111244 http://dx.doi.org/10.1093/cid/ciab537 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
spellingShingle | Major Articles and Commentaries Stone, Mars Di Germanio, Clara Wright, David J Sulaeman, Hasan Dave, Honey Fink, Rebecca V Notari, Edward P Green, Valerie Strauss, Donna Kessler, Debbie Destree, Mark Saa, Paula Williamson, Phillip C Simmons, Graham Stramer, Susan L Opsomer, Jean Jones, Jefferson M Kleinman, Steven Busch, Michael P Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program |
title | Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program |
title_full | Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program |
title_fullStr | Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program |
title_full_unstemmed | Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program |
title_short | Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program |
title_sort | use of us blood donors for national serosurveillance of severe acute respiratory syndrome coronavirus 2 antibodies: basis for an expanded national donor serosurveillance program |
topic | Major Articles and Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406874/ https://www.ncbi.nlm.nih.gov/pubmed/34111244 http://dx.doi.org/10.1093/cid/ciab537 |
work_keys_str_mv | AT stonemars useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT digermanioclara useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT wrightdavidj useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT sulaemanhasan useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT davehoney useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT finkrebeccav useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT notariedwardp useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT greenvalerie useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT straussdonna useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT kesslerdebbie useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT destreemark useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT saapaula useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT williamsonphillipc useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT simmonsgraham useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT stramersusanl useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT opsomerjean useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT jonesjeffersonm useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT kleinmansteven useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT buschmichaelp useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram AT useofusblooddonorsfornationalserosurveillanceofsevereacuterespiratorysyndromecoronavirus2antibodiesbasisforanexpandednationaldonorserosurveillanceprogram |